Smithfield Trust’s Novartis NVS Stock Holding History

Smithfield Trust’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$139K	Hold	892	–	–	0.01%	442
2026 Q1	$135K	Buy	892 +29	+3%	+$4.45K	0.01%	434
2025 Q4	$118K	Buy	863 +89	+11%	+$11.7K	0.01%	448
2025 Q3	$99K	Sell	774 -250	-24%	-$30.5K	﹤0.01%	460
2025 Q2	$122K	Buy	1,024 +44	+4%	+$4.96K	0.01%	419
2025 Q1	$109K	Buy	980 +163	+20%	+$17.4K	0.01%	424
2024 Q4	$79K	Hold	817	–	–	﹤0.01%	481
2024 Q3	$94K	Hold	817	–	–	﹤0.01%	462
2024 Q2	$86K	Sell	817 -13	-2%	-$1.3K	﹤0.01%	465
2024 Q1	$80K	Buy	830 +13	+2%	+$1.33K	﹤0.01%	487
2023 Q4	$81K	Sell	817 -2,044	-71%	-$197K	﹤0.01%	474
2023 Q3	$292K	Sell	2,861 -454	-14%	-$46.1K	0.02%	244
2023 Q2	$334K	Sell	3,315 -1,500	-31%	-$150K	0.02%	242
2023 Q1	$444K	Hold	4,815	–	–	0.03%	202
2022 Q4	$439K	Sell	4,815 -270	-5%	-$22.7K	0.03%	193
2022 Q3	$386K	Sell	5,085 -1,016	-17%	-$84.2K	0.03%	195
2022 Q2	$518K	Buy	6,101 +1,016	+20%	+$89.1K	0.04%	162
2022 Q1	$449K	Sell	5,085 -400	-7%	-$34.6K	0.03%	194
2021 Q4	$481K	Hold	5,485	–	–	0.03%	194
2021 Q3	$450K	Hold	5,485	–	–	0.03%	190
2021 Q2	$500K	Sell	5,485 -80	-1%	-$7.12K	0.03%	180
2021 Q1	$475K	Hold	5,565	–	–	0.03%	187
2020 Q4	$526K	Hold	5,565	–	–	0.04%	171
2020 Q3	$484K	Hold	5,565	–	–	0.04%	168
2020 Q2	$486K	Sell	5,565 -110	-2%	-$9.49K	0.04%	164
2020 Q1	$467K	Buy	5,675 +5,070	+838%	+$452K	0.05%	146
2019 Q4	$57K	Hold	605	–	–	0.01%	500
2019 Q3	$53K	Hold	605	–	–	0.01%	516
2019 Q2	$55K	Sell	605 -210	-26%	-$17.8K	0.01%	507
2019 Q1	$70K	Hold	815	–	–	0.01%	453
2018 Q4	$63K	Hold	815	–	–	0.01%	439
2018 Q3	$63K	Hold	815	–	–	0.01%	489
2018 Q2	$55K	Sell	815 -513	-39%	-$35.4K	0.01%	520
2018 Q1	$96K	Sell	1,328 -190	-13%	-$14.5K	0.01%	409
2017 Q4	$114K	Buy	1,518 +262	+21%	+$19.8K	0.01%	384
2017 Q3	$97K	Buy	1,256 +637	+103%	+$48.1K	0.01%	402
2017 Q2	$46K	Hold	619	–	–	0.01%	531
2017 Q1	$41K	Sell	619 -2,327	-79%	-$155K	0.01%	552
2016 Q4	$192K	Sell	2,946 -4,216	-59%	-$273K	0.03%	291
2016 Q3	$506K	Sell	7,162 -112	-2%	-$8.16K	0.09%	130
2016 Q2	$538K	Buy	7,274 +2,034	+39%	+$141K	0.1%	128
2016 Q1	$340K	Buy	5,240 +5,128	+4,579%	+$349K	0.07%	179
2015 Q4	$9K	Hold	112	–	–	﹤0.01%	705
2015 Q3	$9K	Hold	112	–	–	﹤0.01%	688
2015 Q2	$10K	Hold	112	–	–	﹤0.01%	698
2015 Q1	$10K	Hold	112	–	–	﹤0.01%	694
2014 Q4	$9K	Hold	112	–	–	﹤0.01%	692
2014 Q3	$9K	Sell	112 -111	-50%	-$8.98K	﹤0.01%	715
2014 Q2	$18K	Hold	223	–	–	﹤0.01%	660
2014 Q1	$17K	Hold	223	–	–	﹤0.01%	652
2013 Q4	$16K	Hold	223	–	–	﹤0.01%	640
2013 Q3	$15K	Sell	223 -223	-50%	-$14.8K	﹤0.01%	612
2013 Q2	$28K	Buy	+446	New	+$29K	0.01%	539

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Smithfield Trust's NVS Position: Q2 2026 in Review

Smithfield Trust held its Novartis (NVS) position steady in Q2 2026 at 892 shares worth $139K. The position accounts for 0.01% of the portfolio, ranked #442.

Smithfield Trust first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $538K in Q2 2016. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Smithfield Trust held 892 shares of Novartis worth $139K as of Q2 2026.
Smithfield Trust left its Novartis share count unchanged in Q2 2026.
Novartis made up 0.01% of Smithfield Trust's portfolio in Q2 2026, its #442 holding.
Smithfield Trust first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
Smithfield Trust's Novartis position peaked at $538K in Q2 2016.
1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Smithfield Trust's 13F filing for Q2 2026, filed 5 Aug 2026.